Verastem, Inc. Annual Report: Your Investor's Guide to the Year

This guide breaks down Verastem, Inc.'s latest annual report (10-K) for the fiscal year ended December 31, 2023. We'll cut through the jargon to give you a clear, investor-focused overview of the company's performance, financial health, and future prospects. Our goal is to provide straightforward information to help you understand Verastem's journey and make informed investment decisions.

Here's what we'll cover for the fiscal year ended December 31, 2023:

1. What does this company do and how did they perform this year?

Verastem is a biotechnology company focused on finding, developing, and bringing new cancer medicines to market. As a 'clinical-stage' company, their drugs are currently in human testing, not yet approved for sale.

Their lead drug candidates are Avutometinib and Defactinib.

Avutometinib, a pill that targets two specific pathways (RAF/MEK) involved in cancer growth, is their primary drug candidate. In 2023, Verastem advanced its development, especially for:

• Recurrent Low-Grade Serous Ovarian Cancer (LGSOC): They announced positive early results from their Phase 2 RAMP 201 study. These results showed the drug was promising in terms of how well it worked and how safe it was. The study continues, and Verastem is getting ready to discuss these findings with regulatory bodies, such as the FDA.
• KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC): They kept enrolling patients in the Phase 3 RAMP 301 study, which combines Avutometinib with Defactinib. This is a crucial study designed to support regulatory approval.

Defactinib, another pill that targets the FAK pathway, is mainly studied alongside other treatments, including Avutometinib.

While Verastem didn't achieve any major drug approvals or sales milestones in 2023, advancing their drug development, particularly the positive early data for Avutometinib in LGSOC, marked a significant step forward. They also maintained partnerships with companies like Pfizer and Genfleet Therapeutics, which could bring in future payments if certain development and sales goals are met.

2. Financial performance - revenue, profit, growth metrics

Verastem's financial results for 2023 highlight its focus as a drug development company heavily investing in research and development.

• Total Revenue: The company generated approximately $12.5 million in total revenue in 2023, down from $15.8 million in 2022. This revenue mainly came from collaboration agreements and milestone payments, not from selling products.
• Net Loss: The company reported a net loss of approximately $125.3 million for 2023, compared to $105.7 million in 2022. This larger loss was mainly due to increased research and development (R&D) expenses as their drug studies, especially the crucial RAMP 301 trial, progressed.
• Research & Development (R&D) Expenses: R&D expenses rose to $105.1 million in 2023 from $88.9 million in 2022, reflecting the costs of their ongoing clinical trials for Avutometinib and Defactinib.
• General & Administrative (G&A) Expenses: General and administrative (G&A) expenses were $35.6 million in 2023, up from $32.1 million in 2022, covering company operations and preparations for potential future drug sales.

These numbers underscore the substantial investment needed to bring new drugs to market. Profitability remains a future goal, dependent on successful clinical trials and regulatory approvals.

3. Major wins and challenges this year

Major Wins:

• Positive Clinical Data: The most significant win was the positive early results from the Phase 2 RAMP 201 study of Avutometinib in recurrent LGSOC, which could potentially speed up its path to market.
• Advancement of Crucial Study: Continued enrollment and progress in the Phase 3 RAMP 301 study for KRAS-mutated NSCLC is vital for their lead drug candidate.
• Strategic Financing: Securing a $150 million debt financing deal in January 2023 gave them crucial funds for ongoing operations and drug development.

Challenges:

• Increased Net Loss: The substantial increase in R&D expenses resulted in a larger net loss, highlighting the rapid spending common for drug development companies.
• Capital Needs: Despite recent financing, the company still needs substantial capital to fund its many drugs in development. This could lead to further dilution for existing shareholders, meaning their ownership stake would be smaller.
• Milestone Dependency: Much of their potential future revenue depends on reaching specific development, approval, and sales goals with partners, which are not guaranteed.
• Customer Concentration: Although not a major revenue source yet, the company faces a risk if a few key partners or distributors owe them money, which could affect cash flow if problems occur.

4. Financial health - cash, debt, liquidity

Verastem's financial health reflects its ongoing need to fund significant research and development.

• Cash Position: As of December 31, 2023, Verastem had approximately $150.1 million in cash, cash equivalents, and easily sellable investments. This is a crucial resource for funding their operations.
• Debt: The company's total debt was about $148.5 million at the end of 2023, mainly from the $150 million debt financing deal secured earlier in the year. This debt requires interest payments and repayment.
• Liquidity and Runway: Verastem spent approximately $115.0 million on operations in 2023. Based on their current cash and expected spending rate, they project having enough funds to operate until late 2024 or early 2025. However, they will likely need more capital to finish key studies, prepare for potential drug sales, and develop more drugs. This means they will probably seek additional funding, possibly by issuing new shares or taking on more debt.

5. Key risks that could hurt the stock price

Investing in Verastem, like many biotech companies, comes with specific risks:

• Clinical Trial Failures: Verastem's success depends on its drug studies. If Avutometinib or Defactinib fail to achieve their main goals in current or future trials (like RAMP 201, RAMP 301), it could severely impact the stock price.
• Regulatory Setbacks: Failing to get required approvals from regulators (like the FDA or EMA) for their drugs, or delays in this process, would greatly delay or even prevent them from selling the drugs.
• Competition: The cancer treatment market is highly competitive. Other companies might develop more effective or safer treatments, or launch similar therapies faster, reducing Verastem's potential sales.
• Intellectual Property (IP) Risk: Challenges to their patents or failing to properly protect their intellectual property could allow competitors to develop similar products, affecting future revenue.
• Financing Risk & Dilution: The company will need a lot more money. Issuing new shares in the future could reduce the value of current shares, while taking on more debt could increase their debt burden and repayment duties.
• Dependence on Third Parties: Verastem depends on outside companies (contract research organizations) to run its clinical trials and other companies (contract manufacturing organizations) to produce its drugs. Any problems with these partners could disrupt drug development.
• Product Commercialization Risk: Even if a drug gets approved, successfully launching and selling it is difficult. It requires strong sales, marketing, and distribution networks.

6. Competitive positioning

Verastem operates in highly competitive oncology markets, particularly for KRAS-mutated cancers and LGSOC.

• KRAS-Mutated Cancers: This is an area of intense research, with many large pharmaceutical companies and other biotechs developing drugs that target KRAS (like Amgen's Lumakras and Mirati's Krazati) and other specific therapies. Verastem's Avutometinib, by targeting both RAF and MEK pathways, aims to offer a unique strategy that could potentially overcome drug resistance seen with single-target treatments.
• Low-Grade Serous Ovarian Cancer (LGSOC): This is a rarer type of ovarian cancer, but competition still comes from standard chemotherapy and other experimental drugs. Avutometinib's promising early results position it as a potential leader in this area, which currently has few treatment options.

Verastem's strategy involves using its drugs' unique ways of working and forming strategic partnerships to compete effectively against larger, more established companies.

7. Leadership or strategy changes

Verastem reported no significant changes to its executive leadership team or Board of Directors in 2023. The company continues to carry out its strategy of advancing its cancer drug pipeline.

The "Stock Option Exchange Program," launched in 2024 (after the 2023 fiscal year), is a common tactic for biotech companies to motivate and keep key employees, especially if the stock price has changed. This program connects employee goals with the company's long-term success and is part of their wider incentive plans (from 2012, 2021, and recruitment incentive programs) designed to attract and retain top scientific and management talent.

8. Future outlook

Verastem's future largely depends on the continued success of its drug development programs and its ability to secure additional funding.

• Key Catalysts for 2024 and Beyond:
  • Avutometinib in LGSOC (RAMP 201): Expect more study results and potential talks with regulators (like pre-approval meetings with the FDA). These could speed up the approval process.
  • Avutometinib in KRAS-Mutated NSCLC (RAMP 301): Continued patient enrollment and eventual release of results from this crucial Phase 3 study will be critical.
  • Pipeline Expansion: They may also expand their drug pipeline by finding new uses or drug combinations for Avutometinib and Defactinib.
• Financial Outlook: Verastem will likely need to secure more funding in the future to finish its drug studies and prepare for potential drug sales.
• Partnerships: Continued collaboration with partners like Pfizer and Genfleet could lead to future milestone payments and expanded market reach.

The company's ability to achieve these milestones and manage its capital effectively will be crucial for its long-term growth and shareholder value.

9. Market trends or regulatory changes affecting them

Verastem operates within the dynamic and highly regulated pharmaceutical industry.

• Targeted Oncology Growth: The market for targeted cancer therapies, especially for cancers with specific genetic markers like KRAS-mutated tumors, is growing rapidly. This growth is fueled by scientific breakthroughs and the need for better treatments.
• Regulatory Environment: The FDA offers pathways like accelerated approval and special status for rare diseases (which Avutometinib has for LGSOC). These can greatly affect how quickly drugs are developed and reach patients. Any changes in regulatory requirements or standards could impact Verastem's programs.
• Drug Pricing and Reimbursement: Changing healthcare policies and pressure on drug pricing and how much insurers will pay could affect whether future products can be profitably sold.
• Biotech Funding Landscape: The broader economic environment and investor sentiment towards the biotech sector can influence Verastem's ability to raise capital.

Verastem's success will depend on its ability to navigate these complex scientific, regulatory, and market landscapes.